ANDA Deficiencies Persist Despite QbR; Reviews to Focus More on Excipients
This article was originally published in The Gold Sheet
Despite full adoption of question-based review in the generic drug industry, some of the chemistry and bioequivalence issues QbR was meant to help resolve have persisted, say officials from FDA’s Office of Generic Drugs.
You may also be interested in...
The quality of DMFs is expected to improve thanks to a soon to be released question- based review system for DMF holders as well a recently issued draft guidance calling for new procedures for reviewing master files called “completeness assessments,” said a pharmaceutical industry official who was a former team leader in FDA’s Office of Generic Drugs.
Coalition and GPhA expect to be on the same page at FDA public meeting, but Mylan proposes alternative user fee structure based on establishment fees.
First to file, worst to file? FDA looks to turn the tables on the generics submissions race and award first-to-file status to ANDA applicants who invest in quality by design. Agency urges generics firms to adopt QbD approach by 2011. The problem is many non-QbD first-to-file ANDAs languish in review while firms learn how to make the products, wasting industry and FDA resources - especially with complex modified-release products. Once in production, recalls and warning letters could follow while firms continue learning the hard way.